Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study.
Puranik AD, Dev ID, Rangarajan V, Jain Y, Patra S, Purandare NC, Sahu A, Choudhary A, Bhattacharya K, Gupta T, Chatterjee A, Dasgupta A, Moiyadi A, Shetty P, Singh V, Sridhar E, Sahay A, Shah A, Menon N, Ghosh S, Choudhury S, Shah S, Agrawal A, Lakshminarayanan N, Kumar A, Gopalakrishna A. Puranik AD, et al. Among authors: sridhar e. Neuroradiology. 2024 Nov 11. doi: 10.1007/s00234-024-03495-9. Online ahead of print. Neuroradiology. 2024. PMID: 39527264
Imaging of supratentorial ependymomas with radio-pathological correlation.
Sahu A, Venkatesh A, Snehil A, Mahajan A, Janu A, Sahay A, Sridhar E. Sahu A, et al. Among authors: sridhar e. Explor Target Antitumor Ther. 2024;5(3):766-779. doi: 10.37349/etat.2024.00245. Epub 2024 Jun 27. Explor Target Antitumor Ther. 2024. PMID: 38966175 Free PMC article.
PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center.
Puranik AD, Dev ID, Rangarajan V, Kulkarni S, Shetty N, Gala K, Sahu A, Bhattacharya K, Dasgupta A, Chatterjee A, Gupta T, Sridhar E, Sahay A, Shetty P, Singh V, Moiyadi A, Menon N, Purandare NC, Agrawal A, Shah S, Choudhury S, Ghosh S, Jha AK. Puranik AD, et al. Among authors: sridhar e. Neurol India. 2024 Mar 1;72(2):278-284. doi: 10.4103/NI.Neurol-India-D-23-00252. Epub 2024 Apr 30. Neurol India. 2024. PMID: 38691470 Free article.
A Retrospective Cohort Study to Evaluate the Outcomes of HIV-Associated High-Grade B-Cell Non-Hodgkin Lymphoma (NHL) Treated with Dose Adjusted EPOCH (+/-R) Regimen.
Thorat J, Sengar M, Chanana R, Kapoor A, Singh A, Bonda A, Menon H, Bagal B, Laskar S, Khanna N, Goda JS, Sridhar E, Gujral S, Agarwal A, Sawant S, Daddi A, Shet T, Ghandade N, Jain H. Thorat J, et al. Among authors: sridhar e. Indian J Hematol Blood Transfus. 2024 Jan;40(1):36-42. doi: 10.1007/s12288-023-01652-3. Epub 2023 Apr 21. Indian J Hematol Blood Transfus. 2024. PMID: 38312196
Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas.
Sengar M, Jain H, Shet T, Sridhar E, Gota V, Rangarajan V, Laskar SS, Alahari A, Thorat J, Agarwal A, Sharma N, Gupta H, Kannan S, Kumar S, Nayak L, Menon H, Gujral S, Bagal B. Sengar M, et al. Among authors: sridhar e. Br J Haematol. 2023 Feb;200(4):429-439. doi: 10.1111/bjh.18532. Epub 2022 Nov 2. Br J Haematol. 2023. PMID: 36323643 Clinical Trial.
Outcomes of COVID-19 and risk factors in patients with cancer.
Sengar M, Chinnaswamy G, Ranganathan P, Ashok A, Bhosale S, Biswas S, Chaturvedi P, Dhamne C, Divatia J, D'Sa K, Jain H, Laskar S, Moulik NR, Mummudi N, Nair S, Nayak L, Nayak P, Patkar S, Pawaskar P, Ramaswamy A, Shetty O, Singh A, Sridhar E, Thorat J, Badwe R, Pramesh CS; TMH COVID-19 action group. Sengar M, et al. Among authors: sridhar e. Nat Cancer. 2022 May;3(5):547-551. doi: 10.1038/s43018-022-00363-4. Epub 2022 Apr 4. Nat Cancer. 2022. PMID: 35379984
Clinical outcomes and prognostic factors in children with B-cell lymphoblastic lymphoma (LBL) treated according to on modified BFM-90 protocol: Experience from a Tertiary cancer care center in India.
Vijayasekharan K, Kc A, Prasad M, Dhamne C, Roy Moulik N, Shet T, Sridhar E, Laskar S, Kembhavi S, Shah S, Gujral S, Narula G, Banavali SD. Vijayasekharan K, et al. Among authors: sridhar e. Pediatr Hematol Oncol. 2022 Aug;39(5):427-440. doi: 10.1080/08880018.2021.2005725. Epub 2022 Feb 18. Pediatr Hematol Oncol. 2022. PMID: 35179438
68 results